Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients.
Plasmapheresis (PP) is often employed in the treatment of recurrent focal segmental glomerulosclerosis (FSGS) in the renal allograft, where it appears to be effective in the pediatric population. The efficacy of PP in adults and predictors of response are not well documented. We analyzed the records of 13 adult patients from three transplant centers who underwent PP for recurrent FSGS between 1993 and 1999. One patient (8%) had a complete response, one (8%) had a partial response, and 3 (23%) partially responded but remain PP-dependent. All 5 responders were started on PP within 30 days of recurrence, while 7 of the 8 non-responders initiated PP after a delay of at least 42 days (p = 0.0047). FSGS recurred within 30 days of transplantation in all 5 responders, while 4 of 8 non-responders had no evidence of recurrence until 42-150 days after transplantation (p = 0.098). Post-transplant biopsies were examined in 10 patients and revealed either cellular (6) or collapsing (4) variants of FSGS. We conclude PP is less effective in adults than in children as a treatment for recurrent FSGS in the renal allograft. Predictors of response to PP include early initiation of treatment after recurrence and possibly an early recurrence of disease.
Matalon
A
A
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, 10032, USA.
Markowitz
G S
GS
Joseph
R E
RE
Cohen
D J
DJ
Saal
S D
SD
Kaplan
B
B
D'Agati
V D
VD
Appel
G B
GB
D000328:Adult; D005260:Female; D005923:Glomerulosclerosis, Focal Segmental / Q000209:etiology* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007668:Kidney / Q000473:pathology / Q000601:surgery; D007676:Kidney Failure, Chronic / Q000473:pathology / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome